Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Another article on the Intel's Penryn, next generation of PCs.
For those who are wary or discouraged by Dutton's one year target of .75 I would point out another stock that Dutton has followed and recommended, DXPE. Dutton did an initial report on DXPE when it was $4 and gave a one year target of $6.25. Within a year DXPE hit$50 plus. DXPE did it through acquisitions that were accretive to earnings. However, my suggestion to Turley would be that we get into the same business as Swartz/Lincoln Ventures :)
Share
New Message
Please login to post a reply